Baseline characteristics and treatment outcomes in prescription opioid dependent patients with and without co-occurring psychiatric disorder
- 12 November 2013
- journal article
- research article
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 40 (2) , 157-162
Abstract
Background: Given the growing prevalence of prescription opioid dependence and the considerable rates of additional psychopathology in drug dependence, we examined the association between the presence of a co-occurring Axis I psychiatric disorder and sociodemographic and clinical characteristics in this secondary analysis of patients entering a treatment study for dependence on prescription opioids. Treatment outcomes were also compared. Methods: Patients dependent on prescription opioids participated in a multi-site, two-phase, randomized, controlled trial to assess different lengths of buprenorphine-naloxone pharmacotherapy and different intensities of counseling (Clinicaltrials.gov identifier: NCT00316277). Among the 653 participants entering the first phase of the trial, 360 entered the second phase, receiving 12 weeks of buprenorphine-naloxone treatment; they are reported here. Half of those participants (180/360) had a current co-occurring psychiatric disorder in addition to substance dependence. Results: Sociodemographic characteristics were similar overall between those with and without a co-occurring psychiatric disorder, but women were 1.6 times more likely than men to have a co-occurring disorder. On several clinical indicators at baseline, participants with a co-occurring disorder had greater impairment. However, they had better opioid use outcomes at the conclusion of 12 weeks of buprenorphine-naloxone stabilization than did participants without a co-occurring disorder. Conclusions: Prescription opioid–dependent patients with a co-occurring psychiatric disorder had a better response to buprenorphine-naloxone treatment despite demonstrating greater impairment at baseline. Additional research is needed to determine the mechanism of this finding and to adapt treatments to address this population.Keywords
This publication has 28 references indexed in Scilit:
- Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid DependenceArchives of General Psychiatry, 2011
- How Do Prescription Opioid Users Differ From Users of Heroin or Other Drugs in Psychopathology: Results From the National Epidemiologic Survey on Alcohol and Related ConditionsJournal of Addiction Medicine, 2011
- Effect of Psychiatric Severity on the Outcome of Methadone Maintenance TreatmentEuropean Addiction Research, 2010
- A multi-site, two-phase, Prescription Opioid Addiction Treatment Study (POATS): Rationale, design, and methodologyContemporary Clinical Trials, 2010
- Clinical characteristics of treatment-seeking prescription opioid vs. heroin-using adolescents with opioid use disorderDrug and Alcohol Dependence, 2009
- Mental health and alcohol, drugs and tobacco: a review of the comorbidity between mental disorders and the use of alcohol, tobacco and illicit drugsDrug and Alcohol Review, 2006
- Lifetime Comorbidity of DSM-IV Mood and Anxiety Disorders and Specific Drug Use DisordersThe Journal of Clinical Psychiatry, 2006
- Buprenorphine Treatment of Refractory DepressionJournal of Clinical Psychopharmacology, 1995
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- The Fagerström Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance QuestionnaireBritish Journal of Addiction, 1991